Episode
New treatment for depression
- Podcast
- Dr. John Campbell
- Published
- Jul 22, 2026
- Duration seconds
- 1707
- Processing state
not_requested- Canonical source
- https://traffic.megaphone.fm/VG9569037795.mp3
Actions
POST https://stenobird.com/v1/public/podcasts/dr-john-campbell-7851784/episodes/new-treatment-for-depression/transcription-requests
Idempotently request low-priority transcript generation for this episode.GET https://stenobird.com/podcast/dr-john-campbell-7851784/new-treatment-for-depression.md
Read the agent-friendly Markdown representation of this episode resource.
Summary
Boom in psychedelic therapies? https://www.telegraph.co.uk/news/2022/08/20/magic-mushrooms-set-become-uks-ultimate-weapon-against-depression/ https://www.theguardian.com/science/2022/apr/12/psilocybin-depression-brain-break-out-of-a-rut-magic-mushrooms Short-acting drugs, psychedelic experience, two-hour therapy session. Resetting brain networks Helping to end ingrained negative patterns of thought, and making patients far more receptive to therapy. Small Pharma https://smallpharma.com Leading the world’s first regulated clinical trial, DMT (dimethyltryptamine) with psychotherapy for major depressive disorder. Phase one done on healthy volunteers Next few months, reports from 42 patients Dr Carol Routledge, chief medical and scientific officer We think that this treatment will really get to the root cause, rather than just dampening symptoms Almost immediate benefits Based on initial data that we already have, and other companies have, there’s going to be a fairly immediate impact In terms of the psychedelic experience, we’re talking about 20 minutes, and then the integration therapy afterwards, we expect the antidepressant activity to be extremely durable … to last maybe three, four or five months Imaging data Psychedelics work on the brain networks Making neural connections more flexible to brain plasticity You can reset those networks in the brain, and then that leaves the brain much more receptive to therapy, which is why we bring it in straight afterwards Medicines and Healthcare products Regulatory Agency (MHRA) Innovative Licensing and Access Pathway (ILAP) Brings organisations together Speed up the time getting meds to patients Other companies testing MDMA 3,4-Methylenedioxymethamphetamine Therapy for post-traumatic stress disorder (PTSD) Psilocybin, (Clerkenwe…